Rxo (RXO) Capital Expenditures (2021 - 2026)

Rxo (RXO) has reported Capital Expenditures for 6 consecutive years, with $17.0 million the latest figure, recorded in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $17.0 million, up 13.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $61.0 million (up 24.49% YoY), and the FY2025 annual result was $59.0 million, up 31.11% from the prior year.
• Capital Expenditures was $17.0 million for Q1 2026 at Rxo, up from $16.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $18.0 million in Q4 2022 and troughed at $11.0 million in Q1 2024.
• Average Capital Expenditures over 5 years is $14.2 million, with a median of $14.0 million recorded in 2025.
• Year-over-year, Capital Expenditures jumped 100.0% in 2022 and sank 38.89% in 2024.
• Over 5 years, Capital Expenditures stood at $18.0 million in 2022, then changed by 0.0% to $18.0 million in 2023, then tumbled by 33.33% to $12.0 million in 2024, then jumped by 33.33% to $16.0 million in 2025, then increased by 6.25% to $17.0 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $17.0 million in Q1 2026, $16.0 million in Q4 2025, and $14.0 million in Q3 2025.